Physician profile
Gian Carlo Rossi
NPI 1497142178
$52,281.73
in general payments reported to CMS, 2019-2025
17 companies · $34K in 2025
The $34K reported for 2025 was more than what 97% of Neurology With Special Qualifications In Child Neurology providers received nationally (typical 2025 total: $275).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14.74 · 2020: $128 · 2021: $737 · 2022: $282 · 2023: $518 · 2024: $16K · 2025: $34K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $45K · Consulting Fee: $2,600 · Travel and Lodging: $2,020 · Food and Beverage: $1,895 · Education: $16.72.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $44,587.50 |
| Consulting Fee | $2,600.00 |
| Travel and Lodging | $2,020.46 |
| Food and Beverage | $1,895.08 |
| Education | $16.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acadia Pharmaceuticals INC | $50,091.97 | 2023-2025 | Daybue |
| Livanova USA, INC. | $615.27 | 2021-2025 | Vns Therapy Sentiva Model 1000 Generator |
| Ucb, INC. | $568.25 | 2021-2025 | Fintepla, Briviact |
| Jazz Pharmaceuticals INC. | $176.53 | 2022-2025 | |
| Immedica Pharma US, INC. | $170.28 | 2022-2023 | |
| Eisai INC. | $131.30 | 2020-2022 | |
| Zogenix INC. | $124.67 | 2021 | |
| Neurelis, INC. | $102.24 | 2021-2025 | Valtoco |
| Otter Pharmaceuticals, LLC | $72.51 | 2025 | Sympazan |
| Greenwich Biosciences, INC. | $48.83 | 2020-2021 | |
| Cycle Pharmaceuticals INC | $47.68 | 2025 | Tascenso Odt, Bafiertam |
| Azurity Pharmaceuticals, INC. | $43.40 | 2023-2025 | Zonisade, Eprontia, Fleqsuvy |
| Aquestive Therapeutics, INC. | $25.58 | 2020-2022 | |
| Catalyst Pharmaceuticals, INC. | $16.72 | 2024 | |
| Biocodex, INC. | $15.96 | 2023 | Diacomit |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $15.80 | 2021 | |
| Travere Therapeutics, INC. | $14.74 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gian Rossi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.